2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2763

Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar Pharmacokinetics and Pharmacodynamics Profiles in Japanese and Caucasian Healthy Volunteers

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2597

Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2448

Flare Definitions for Juvenile Idiopathic Arthritis (JIA) Based on ACR Core Set Variables and Patient Reported Outcomes: Results from the Research in Arthritis in Canadian Children-Emphasizing Outcomes Prospective Cohort

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

9:00AM-11:00AM: Abstract Number: 2664

Flares Occur Frequently in RA Patients Undergoing Arthroplasty

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 3009

Fli1 Deficiency Contributes to the Downregulation of Endothelial Protein C Receptor in Systemic Sclerosis: A Possible Role in Pro-Thrombotic Condition

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2698

Follicular Helper T Cells in Peripheral Blood of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2390

Foot Kinematics and Foot Center of Pressure and Their Association with Medial Knee Load Reduction with Use of Flexible Shoes in Knee Osteoarthritis

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2373

Frequency of Antinuclear (ANA), Myositis-Specific (MSA) and Myositis-Associated Antibodies (MAA) in Patients with Idiopathic Inflammatory Myopathies (IIM) from Mexico, Central and South America Centers: Data from the Panlar Myositis Study Group.

Muscle Biology, Myositis and Myopathies Poster II: Autoantibodies and Treatments in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 3062

Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia

Vasculitis Poster III

9:00AM-11:00AM: Abstract Number: 2556

Functional Genetics of PTPN2 in Rheumatoid Arthritis: Haploinsufficiency of PTPN2 Promotes Severity of CD4+ T-Cell Mediated Autoimmune Arthritis

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2808

Genetic Variants at Chromosome 5q15 Associated with Immune-Mediated Diseases Influence Gene Expression and Isoform Profile of the Endoplasmic Reticulum Aminopeptidase

Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology Poster I

9:00AM-11:00AM: Abstract Number: 2995

Genome Wide Analysis in Scleroderma Renal Crisis: Defining Genetic Risk in Patients with RNA Polymerase III Auto-Antibodies

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster II

9:00AM-11:00AM: Abstract Number: 2696

Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2236

Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2509

Glucocorticoid Induced Osteoporosis Screening and Treatment: A Gender Comparison in a Cohort of Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting

Quality Measures and Quality of Care Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].